Alligator Bioscience Past Earnings Performance
Past criteria checks 0/6
Alligator Bioscience's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 18.9% per year.
Key information
-7.0%
Earnings growth rate
10.7%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -18.9% |
| Return on equity | -802.5% |
| Net Margin | -526.2% |
| Next Earnings Update | 13 Jul 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Alligator Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 40 | -213 | 72 | 0 |
| 31 Dec 22 | 36 | -193 | 69 | 0 |
| 30 Sep 22 | 21 | -177 | 65 | 0 |
| 30 Jun 22 | 20 | -163 | 63 | 0 |
| 31 Mar 22 | 18 | -152 | 59 | 0 |
| 31 Dec 21 | 13 | -142 | 57 | 0 |
| 30 Sep 21 | 8 | -139 | 54 | 0 |
| 30 Jun 21 | 5 | -133 | 51 | 0 |
| 31 Mar 21 | 6 | -133 | 53 | 0 |
| 31 Dec 20 | 6 | -143 | 56 | 0 |
| 30 Sep 20 | 5 | -169 | 59 | 0 |
| 30 Jun 20 | 9 | -194 | 62 | 0 |
| 31 Mar 20 | 4 | -209 | 62 | 0 |
| 31 Dec 19 | 4 | -210 | 61 | 0 |
| 30 Sep 19 | 30 | -181 | 60 | 0 |
| 30 Jun 19 | 26 | -164 | 58 | 0 |
| 31 Mar 19 | 26 | -152 | 55 | 0 |
| 31 Dec 18 | 27 | -150 | 52 | 0 |
| 30 Sep 18 | 53 | -107 | 54 | 0 |
| 30 Jun 18 | 54 | -93 | 51 | 0 |
| 31 Mar 18 | 55 | -86 | 48 | 0 |
| 31 Dec 17 | 57 | -64 | 44 | 0 |
| 30 Sep 17 | 12 | -96 | 40 | 0 |
| 30 Jun 17 | 15 | -77 | 37 | 0 |
| 31 Mar 17 | 18 | -91 | 35 | 0 |
| 31 Dec 16 | 59 | -48 | 33 | 0 |
| 30 Sep 16 | 55 | -68 | 31 | 0 |
| 31 Dec 15 | 292 | 207 | 32 | 0 |
| 31 Dec 14 | 1 | -77 | 31 | 0 |
Quality Earnings: ATORXS is currently unprofitable.
Growing Profit Margin: ATORXS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATORXS is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare ATORXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATORXS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: ATORXS has a negative Return on Equity (-802.5%), as it is currently unprofitable.